Call +44 (0)1904 798634 or +44 (0)7550 079918

Leading provider of life science market reports and research services

EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2025

Be the first to review this product

EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2025

Summary

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV can cause both acute and chronic...
You can choose to pay by purchase order during checkout

Availability: In stock

$3,995.00

* Required Fields

You can choose to pay by purchase order during checkout
GlobalData.

Digital downloads direct to your inbox within 24 hours.

First class customer service from our team of experts.

Pay by credit card or request an invoice

Product Description

Details

EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2025

Summary

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV can cause both acute and chronic hepatitis infection. According to the World Health Organization (WHO), an estimated 130-150 million individuals worldwide are affected with chronic HCV and about 500,000 people died of HCV-related conditions, including liver cirrhosis and hepatocellular carcinoma (HCC), in 2010 (Lozano et al., 2012; WHO, 2015).

In the 9MM, GlobalData epidemiologists forecast that the anti-HCV+ total prevalent cases will increase from 19,842,780 total prevalent cases in 2015 to 20,886,113 total prevalent cases in 2025, at an Annual Growth Rate (AGR) of 0.53%. China will have the highest number of anti-HCV+ total prevalent cases among the 9MM throughout the forecast period, while Germany will have the lowest number of anti-HCV+ total prevalent cases. In the 9MM, GlobalData epidemiologists forecast that the HCV RNA+ total prevalent cases will increase from 9,932,624 total prevalent cases in 2015, to 10,399,601 total prevalent cases in 2025, at an AGR of 0.47%. In the 9MM, GlobalData epidemiologists forecast that the anti-HCV+ diagnosed prevalent cases will increase from 5,681,205 diagnosed prevalent cases in 2015, to 5,944,944 diagnosed prevalent cases in 2025, at an AGR of 0.46%. In the 9MM, GlobalData epidemiologists forecast that the HCV RNA+ diagnosed prevalent cases will increase from 2,992,433 diagnosed prevalent cases in 2015, to 3,115,901 diagnosed prevalent cases in 2025, at an AGR of 0.41%.

This forecast is supported by historical data from government reports and national studies published in peer-reviewed journals. All data used for the analysis were country-specific. All studies that were used confirmed anti-HCV+ and HCV RNA+ total prevalent cases through laboratory diagnostic tests. Also, GlobalData epidemiologists did not include studies that oversampled the high-risk population groups, such as IDUs, as we believe this would inflate the anti-HCV+ total prevalence. Furthermore, additional segmentation of the anti-HCV+ diagnosed prevalent cases by age, sex, and liver cirrhosis status will provide the most refined and granular forecast results. The forecast methodology was also consistent across the 9MM, thereby allowing for a meaningful comparison of the forecast numbers in these markets.

Scope

- The Hepatitis C Virus (HCV) EpiCast Report provides an overview of the risk factors and global trends of HCV in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and China). It includes a 10-year epidemiological forecast of the anti-HCV+ and HCV RNA+ total prevalent cases (including diagnosed and undiagnosed), which are segmented by sex and age. The anti-HCV+ total prevalent cases are further segmented by genotype, human immunodeficiency virus (HIV) comorbidity, and hepatitis B virus (HBV) comorbidity among the 9MM. Additionally, the report also includes anti-HCV+ and HCV RNA+ diagnosed prevalent cases, which are also segmented by sex and age. The anti-HCV+ diagnosed prevalent cases are segmented by liver cirrhosis status.
- The HCV epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

The HCV EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global HCV market.
- Quantify patient populations in the global HCV market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HCV therapeutics in each of the markets covered.
- Identify the percentage of HCV prevalent cases by genotype, HIV and HBV comorbidity, and liver cirrhosis status.

Additional Information

Additional Information

Publisher name GlobalData.
Format PDF
Page count 102
Publication date 1 Dec 2016
Table of contents 1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 7
1.2 List of Figures 9
2 Epidemiology 10
2.1 Disease Background 10
2.2 Risk Factors and Comorbidities 11
2.3 Global Trends 13
2.3.1 Diagnosed Incidence and Total Prevalence 14
2.3.2 Genotype 20
2.4 Forecast Methodology 20
2.4.1 Sources Used Tables 22
2.4.2 Forecast Assumptions and Methods 32
2.4.3 Sources Not Used 52
2.5 Epidemiological Forecast of HCV (2015-2025) 53
2.5.1 Total Prevalent Cases 53
2.5.2 Diagnosed Prevalent Cases 69
2.6 Discussion 84
2.6.1 Epidemiological Forecast Insight 84
2.6.2 Limitations of the Analysis 85
2.6.3 Strengths of the Analysis 86
3 Appendix 88
3.1 Bibliography 88
3.2 Physicians and Specialists Included in this Study 97
3.3 About the Authors 98
3.3.1 Epidemiologists 98
3.3.2 Reviewers 98
3.3.3 Global Director of Therapy Analysis and Epidemiology 99
3.4 About GlobalData 100
3.5 About EpiCast 100
3.6 Disclaimer 101

Reviews

Write Your Own Review

Only registered users can write reviews. Please, log in or register

Product Tags

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.